1Nemati A,Rahmatabadi ZK,Fatemi A,et al.Hereditary nonpolyposiscolorectal cancer and familial colorectal cancer in Central part ofIran,Isfahan[J].J Res Med Sci,2012,17(1):67-73.
2Jinggui Chen,MD,Qingguo Li,et al.Prognostic Significance ofc-erbB-2 and Vascular Endothelial Growth Factor in ColorectalLiver Metastases[J].Ann Surg Oncol,2010,17(6):1555-1563.
3Friederichs J,Rosenberg R,Mages J,et al.Gene expression profilesof different clinical stages of colorectal carcinoma:toward amolecular genetic understanding of tumor progression[J].Int JColorectal Dis,2005,20(5):391-402.
5Winder T,Mundlein A,Rhomberg S,et al.Different types of K-rasmutations are conversely associated with overall survival in patie-ntswith colorectal cancer[J].Oncology Reports,2009,21(5):1283-1287.
6Rouleau E,Spyratos F,Dieumegard B,et al.KRAS mutation statusin colorectal cancer to predict response to EGFR targeted therapies:the need for a more precise definition[J].Br J Cancer,2008,99(12):2100.
7Zavodna K,KonecnyM,Krivulcik T,et al.Genetic analysis of K-rasmutation status in metastatic colorectal cancer patients[J].Neoplasma,2009,56(3):275-278.
8Jason B,Wright,Seth J,et al.Upregulation of C-myc in cis througha Large Chromatin Loop Linked to a Cancer Risk-AssociatedSingle-Nucleotide Polymorphism in Colorectal Cancer Cells[J].ColeMol Cell Biol,2010,30(6):1411-1420.
9Qu H,Qu D,Chen F,et a1.ZBTB7 ovenrxpression contributes tomalignancy in breast tmncer[J].Cancer Invest,2010,28(6):672-678.
10Zu X,Yu L,Sun Y,et al.Global mapping of ZBTBTA transcriptionfactor binding sites in HepG2 cells[J].Cell Mol Biol Lett,20l0,15(2):260-271.
4Teixeira DM,Peixoto A,Lopes C,et al.Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer[C].Thomas Jefferson University,Porto,2009:35.
5Whitehall V,Tran K,Umapathy A,et al.A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting[J].Journal of Molecular Diagnostics,2009,11 (6):543.
6Taylor CF.Mutation scanning using high-resolution melting[J].Biochemical Society Transactions,2009,37(part 2):433.
7Hung C,Lee C,Chang C,et al.Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis[J].Clin Biochem,2008,41(3):162.
8Liew M,Pryor R,Palais R,et al.Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons[J].Clin Chem,2004,50(10):1156.
9Amado RG,Wolf M,Peeters M,et al.Wild-type Kras is required for panitumumab efficacy in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(10):1626.
10Lievre A,Bachet JB,Boige V,et al.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab[J].J Clin Oncol,2008,26(3):374.
5Locker G, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastroin- testinal cancer[J]. J Clin Oneol, 24(33):5313-5327.
6Chen C C, YangS H, Lin J K, et al. Is it reasonable to add preopera-tive serum level of CEA and CA19-9 to stag- ing for colorectal cancer.9 J]. J Surg Res, 2005,124 (2) :169-174.
7Goonetilleke K S, Siriwardena A K. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer[ J]. Eur J Surg On- col, 2007,33 ( 3 ) : 266-270.
8Kalmar A,Wichmann B,Galamb O,et al. Gene-expression analy- sis of a colorectal cancer-specific discriminatory transcript set on for- malin-fixed,paraffin-embedded (FFPE) tissue samples[J]. Diagnostic Pathology, 2015,10 ( 1 ) : 1-12.
9Spano JP,Milano G,Rixe C,et al. JAK/STAT signalling pathway in colorectal cancer:a new biological target with therapeutic implica- tions[J]. European Journal of Cancer, 2006,42 (16) : 2668-2670.
10Ivashkiv LB. Jak-STAT signaling pathways in cells of the immune system[J]. Reviews in lmmunogenetics,2000,2(2):220-230.
